Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026
Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…
Certara2026 年 3 月 11 日
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle Pillsbury2026 年 3 月 4 日
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
Certara2026 年 3 月 3 日
Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes
We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…
Certara2026 年 2 月 27 日
On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
Certara2026 年 2 月 26 日
FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development
Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…
Certara2026 年 2 月 18 日
